-
Engaging patients for drug repurposing: mapping the patients engagement continuum
Minna Allarakhia
Editorial: Clinical Investigation
-
Engaging patients for drug repurposing: mapping the patients engagement continuum
Minna Allarakhia
Editorial: Clinical Investigation
-
Engaging patients for drug repurposing: mapping the patients engagement continuum
Minna Allarakhia
Editorial: Clinical Investigation
-
Engaging patients for drug repurposing: mapping the patients engagement continuum
Minna Allarakhia
Editorial: Clinical Investigation
-
Engaging patients for drug repurposing: mapping the patients engagement continuum
Minna Allarakhia
Editorial: Clinical Investigation
-
Engaging patients for drug repurposing: mapping the patients engagement continuum
Minna Allarakhia
Editorial: Clinical Investigation
-
Engaging patients for drug repurposing: mapping the patients engagement continuum
Minna Allarakhia
Editorial: Clinical Investigation
-
Engaging patients for drug repurposing: mapping the patients engagement continuum
Minna Allarakhia
Editorial: Clinical Investigation
-
Clinical trial success influenced by biomarker- and receptor-targeted therapies
News and Views: Clinical Investigation
-
Clinical trial success influenced by biomarker- and receptor-targeted therapies
News and Views: Clinical Investigation
-
Clinical trial success influenced by biomarker- and receptor-targeted therapies
News and Views: Clinical Investigation
-
Clinical trial success influenced by biomarker- and receptor-targeted therapies
News and Views: Clinical Investigation
-
Clinical trial success influenced by biomarker- and receptor-targeted therapies
News and Views: Clinical Investigation
-
Clinical trial success influenced by biomarker- and receptor-targeted therapies
News and Views: Clinical Investigation
-
Clinical trial success influenced by biomarker- and receptor-targeted therapies
News and Views: Clinical Investigation
-
Clinical trial success influenced by biomarker- and receptor-targeted therapies
News and Views: Clinical Investigation
-
Clinical progress for enterovirus 71 vaccines: what does the future hold?
Jing-Xin Li, Feng-Cai Zhu
Editorial: Clinical Investigation
-
Clinical progress for enterovirus 71 vaccines: what does the future hold?
Jing-Xin Li, Feng-Cai Zhu
Editorial: Clinical Investigation
-
Clinical progress for enterovirus 71 vaccines: what does the future hold?
Jing-Xin Li, Feng-Cai Zhu
Editorial: Clinical Investigation
-
Clinical progress for enterovirus 71 vaccines: what does the future hold?
Jing-Xin Li, Feng-Cai Zhu
Editorial: Clinical Investigation
-
Clinical progress for enterovirus 71 vaccines: what does the future hold?
Jing-Xin Li, Feng-Cai Zhu
Editorial: Clinical Investigation
-
Clinical progress for enterovirus 71 vaccines: what does the future hold?
Jing-Xin Li, Feng-Cai Zhu
Editorial: Clinical Investigation
-
Clinical progress for enterovirus 71 vaccines: what does the future hold?
Jing-Xin Li, Feng-Cai Zhu
Editorial: Clinical Investigation
-
Clinical progress for enterovirus 71 vaccines: what does the future hold?
Jing-Xin Li, Feng-Cai Zhu
Editorial: Clinical Investigation
-
Therapeutic targeting of tumor angiogenesis: how far have we come?
Bruce C Baguley & Mark J McKeage
Clinical Trail Outcomes: Clinical Investigation
-
Therapeutic targeting of tumor angiogenesis: how far have we come?
Bruce C Baguley & Mark J McKeage
Clinical Trail Outcomes: Clinical Investigation
-
Therapeutic targeting of tumor angiogenesis: how far have we come?
Bruce C Baguley & Mark J McKeage
Clinical Trail Outcomes: Clinical Investigation
-
Therapeutic targeting of tumor angiogenesis: how far have we come?
Bruce C Baguley & Mark J McKeage
Clinical Trail Outcomes: Clinical Investigation
-
Therapeutic targeting of tumor angiogenesis: how far have we come?
Bruce C Baguley & Mark J McKeage
Clinical Trail Outcomes: Clinical Investigation
-
Therapeutic targeting of tumor angiogenesis: how far have we come?
Bruce C Baguley & Mark J McKeage
Clinical Trail Outcomes: Clinical Investigation
-
Therapeutic targeting of tumor angiogenesis: how far have we come?
Bruce C Baguley & Mark J McKeage
Clinical Trail Outcomes: Clinical Investigation
-
Therapeutic targeting of tumor angiogenesis: how far have we come?
Bruce C Baguley & Mark J McKeage
Clinical Trail Outcomes: Clinical Investigation
-
Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia
Meenakshi Devidas, James R Anderson
Clinical Trail Methodology: Clinical Investigation
-
Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia
Meenakshi Devidas, James R Anderson
Clinical Trail Methodology: Clinical Investigation
-
Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia
Meenakshi Devidas, James R Anderson
Clinical Trail Methodology: Clinical Investigation
-
Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia
Meenakshi Devidas, James R Anderson
Clinical Trail Methodology: Clinical Investigation
-
Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia
Meenakshi Devidas, James R Anderson
Clinical Trail Methodology: Clinical Investigation
-
Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia
Meenakshi Devidas, James R Anderson
Clinical Trail Methodology: Clinical Investigation
-
Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia
Meenakshi Devidas, James R Anderson
Clinical Trail Methodology: Clinical Investigation
-
Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia
Meenakshi Devidas, James R Anderson
Clinical Trail Methodology: Clinical Investigation
-
Chemotherapy of advanced non-small-cell lung cancer: current landscape
Athanasios G Pallis, Rafal Dziadziuszko & Mary OBrien
Review: Clinical Trail Outcomes: Clinical Investigation
-
Chemotherapy of advanced non-small-cell lung cancer: current landscape
Athanasios G Pallis, Rafal Dziadziuszko & Mary OBrien
Review: Clinical Trail Outcomes: Clinical Investigation
-
Chemotherapy of advanced non-small-cell lung cancer: current landscape
Athanasios G Pallis, Rafal Dziadziuszko & Mary OBrien
Review: Clinical Trail Outcomes: Clinical Investigation
-
Chemotherapy of advanced non-small-cell lung cancer: current landscape
Athanasios G Pallis, Rafal Dziadziuszko & Mary OBrien
Review: Clinical Trail Outcomes: Clinical Investigation
-
Chemotherapy of advanced non-small-cell lung cancer: current landscape
Athanasios G Pallis, Rafal Dziadziuszko & Mary OBrien
Review: Clinical Trail Outcomes: Clinical Investigation
-
Chemotherapy of advanced non-small-cell lung cancer: current landscape
Athanasios G Pallis, Rafal Dziadziuszko & Mary OBrien
Review: Clinical Trail Outcomes: Clinical Investigation
-
Chemotherapy of advanced non-small-cell lung cancer: current landscape
Athanasios G Pallis, Rafal Dziadziuszko & Mary OBrien
Review: Clinical Trail Outcomes: Clinical Investigation
-
Chemotherapy of advanced non-small-cell lung cancer: current landscape
Athanasios G Pallis, Rafal Dziadziuszko & Mary OBrien
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Missing data in clinical trials: a data interpretation problem with statistical solutions? Interview with James Roger
James Roger
Interview: Clinical Investigation
-
Missing data in clinical trials: a data interpretation problem with statistical solutions? Interview with James Roger
James Roger
Interview: Clinical Investigation
-
Missing data in clinical trials: a data interpretation problem with statistical solutions? Interview with James Roger
James Roger
Interview: Clinical Investigation
-
Missing data in clinical trials: a data interpretation problem with statistical solutions? Interview with James Roger
James Roger
Interview: Clinical Investigation
-
Missing data in clinical trials: a data interpretation problem with statistical solutions? Interview with James Roger
James Roger
Interview: Clinical Investigation
-
Missing data in clinical trials: a data interpretation problem with statistical solutions? Interview with James Roger
James Roger
Interview: Clinical Investigation
-
Missing data in clinical trials: a data interpretation problem with statistical solutions? Interview with James Roger
James Roger
Interview: Clinical Investigation
-
Missing data in clinical trials: a data interpretation problem with statistical solutions? Interview with James Roger
James Roger
Interview: Clinical Investigation
-
Key features of the EXPANSE clinical program for apixaban in the prevention and treatment of thrombotic disorders
Nadia Rosencher, Paul Zufferey, Silvy Laporte, Patrick Mismetti
Review Article: Clinical Investigation
-
Key features of the EXPANSE clinical program for apixaban in the prevention and treatment of thrombotic disorders
Nadia Rosencher, Paul Zufferey, Silvy Laporte, Patrick Mismetti
Review Article: Clinical Investigation
-
Key features of the EXPANSE clinical program for apixaban in the prevention and treatment of thrombotic disorders
Nadia Rosencher, Paul Zufferey, Silvy Laporte, Patrick Mismetti
Review Article: Clinical Investigation
-
Key features of the EXPANSE clinical program for apixaban in the prevention and treatment of thrombotic disorders
Nadia Rosencher, Paul Zufferey, Silvy Laporte, Patrick Mismetti
Review Article: Clinical Investigation
-
Key features of the EXPANSE clinical program for apixaban in the prevention and treatment of thrombotic disorders
Nadia Rosencher, Paul Zufferey, Silvy Laporte, Patrick Mismetti
Review Article: Clinical Investigation
-
Key features of the EXPANSE clinical program for apixaban in the prevention and treatment of thrombotic disorders
Nadia Rosencher, Paul Zufferey, Silvy Laporte, Patrick Mismetti
Review Article: Clinical Investigation
-
Key features of the EXPANSE clinical program for apixaban in the prevention and treatment of thrombotic disorders
Nadia Rosencher, Paul Zufferey, Silvy Laporte, Patrick Mismetti
Review Article: Clinical Investigation
-
Key features of the EXPANSE clinical program for apixaban in the prevention and treatment of thrombotic disorders
Nadia Rosencher, Paul Zufferey, Silvy Laporte, Patrick Mismetti
Review Article: Clinical Investigation
-
Ethical issues in adult oncology randomized clinical trials
Erika P Hamilton, Jeffrey M Peppercorn
Clinical Trail Outcomes: Clinical Investigation
-
Ethical issues in adult oncology randomized clinical trials
Erika P Hamilton, Jeffrey M Peppercorn
Clinical Trail Outcomes: Clinical Investigation
-
Ethical issues in adult oncology randomized clinical trials
Erika P Hamilton, Jeffrey M Peppercorn
Clinical Trail Outcomes: Clinical Investigation
-
Ethical issues in adult oncology randomized clinical trials
Erika P Hamilton, Jeffrey M Peppercorn
Clinical Trail Outcomes: Clinical Investigation
-
Ethical issues in adult oncology randomized clinical trials
Erika P Hamilton, Jeffrey M Peppercorn
Clinical Trail Outcomes: Clinical Investigation
-
Ethical issues in adult oncology randomized clinical trials
Erika P Hamilton, Jeffrey M Peppercorn
Clinical Trail Outcomes: Clinical Investigation
-
Ethical issues in adult oncology randomized clinical trials
Erika P Hamilton, Jeffrey M Peppercorn
Clinical Trail Outcomes: Clinical Investigation
-
Ethical issues in adult oncology randomized clinical trials
Erika P Hamilton, Jeffrey M Peppercorn
Clinical Trail Outcomes: Clinical Investigation
-
Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data
Michael Gnant
Review Article: Clinical Investigation
-
Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data
Michael Gnant
Review Article: Clinical Investigation
-
Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data
Michael Gnant
Review Article: Clinical Investigation
-
Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data
Michael Gnant
Review Article: Clinical Investigation
-
Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data
Michael Gnant
Review Article: Clinical Investigation
-
Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data
Michael Gnant
Review Article: Clinical Investigation
-
Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data
Michael Gnant
Review Article: Clinical Investigation
-
Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data
Michael Gnant
Review Article: Clinical Investigation